Vendor Intelligence Report: UWA Elite Peptides

Executive summary

Across 22 Finnrick lab tests, UWA Elite Peptides records 10 pass / 11 fail — an overall pass rate of 45%. The useful read is not a simple vendor-wide verdict. UWA’s tested catalog is narrow and uneven: Tirzepatide scores better than Retatrutide, while Retatrutide is the weaker default choice; ratings also contract under stricter methodology, consistent with identity and purity looking better than fill-control and process-control.

The sharpest product risk sits inside the better-scored product. Finnrick records an endotoxin-positive Tirzepatide 30mg batch, a failure mode that a purity-only COA would not catch and that makes batch-matched sterility/endotoxin documentation essential. The report also tracks serious quantity variance across early GLP-1 batches, so a clean-looking vial or recent screenshot should not be treated as evidence for the next lot.

Beyond the lab data, UWA’s public identity is more China-facing than its US listing implies. The active Shopify storefront launched the same day its domain was registered, the site names Zuw Biopharma and Hangzhou UWA Peptides, a YouTube channel describes a “factory from China,” and U.S. corporate searches did not recover a matching entity. Domain drift adds friction: an older UWA Elite domain is defunct while a newer UWA Peptides domain sits as a watch item.

The documentation layer is the second major problem. UWA’s test-results page displays a Janoshik COA issued to a third-party client, Forever Young Pharmacy COAs tied into its contact ecosystem, and WhatsApp-distributed images rather than clean lab-portal verification. The promotion scan did not surface a public affiliate-code network, but the visible reviews are screenshots rather than platform-verified reputation.

Inside the full report:

• Appendix A per-product pass/fail data and methodology-divergence charts for Retatrutide and Tirzepatide
• Finnrick endotoxin exhibit for the flagged Tirzepatide 30mg batch and traceability/recall-status analysis
• Corporate-record and site-capture analysis of Zuw Biopharma and Hangzhou UWA Peptides
• Domain-forensics timeline for uwa-biotech.com, uwaelitepeptides.com, and uwapeptides.com
• COA integrity review covering Janoshik, Forever Young Pharmacy, and WhatsApp-sourced images

Risk assessment

• Tirzepatide endotoxin-contamination risk — high: Finnrick field record shows endotoxins detected in Tirzepatide 30mg Batch “Den” on May 2, 2026; purity-style COAs would not catch this failure.
• Retatrutide quantity-accuracy risk — high: Current Finnrick block shows Retatrutide at 13 tests, 5 pass / 8 fail, Finnrick rating 59.67%; it is UWA’s weaker tested product.
• Tirzepatide quantity-accuracy risk — medium: Tirzepatide is better than UWA Retatrutide at 8 tests, 5 pass / 3 fail, 74.41%, but still requires lot-matched verification.
• COA-integrity and documentation-misrepresentation risk — high: UWA displays Janoshik Task #52195 with a third-party client and relies on Forever Young Pharmacy or WhatsApp COAs that buyers cannot verify from the page.
• Corporate-accountability and jurisdictional-recourse risk — medium: The market listing says US, but site/channel evidence points to a China-based Zuw Biopharma operation and searches found no matching U.S. corporate registration.
• Domain-cycling and brand-verification risk — medium: The prior uwaelitepeptides.com does not resolve, uwa-biotech.com is active, and uwapeptides.com is a new placeholder without an observed anti-counterfeit or official-channel list.
• OEM and white-label traceability risk — medium: UWA advertises custom labels, logos and cap colors, creating a realistic risk that its supply appears under other brands without batch-level disclosure.